Lubowicka et al. found that plasma concentration of CCR2 in the BC group and all stages of BC were significantly lower when compared to the healthy controls (in BC groups—0.96 (0.05–8.17), in the total control group—2.30 (0.05–22.60), ng/mL, p < 0.001 in all cases). The gene discussed is CCR2; the disease is breast cancer.